Romidepsin inhibited proliferation and angiogenesis and promoted cell cycle arrest and apoptosis in various cancer cells.688 For previously treated or refractory CTCL patients, romidepsin monotherapy displayed an ORR of 34%.689,690 For R/R PTCL patients, romidepsin monotherapy displayed an ORR of 38%.691 Numerous ongoing clinical trials are investigating romidepsin combined with anti-PD-1 monoclonal antibody, PIs, PI3K inhibitors, BCL2 inhibitors, IMiDs, and chemotherapy in R/R T-cell NHL. Here, PDCD1 is linked to T-cell non-Hodgkin lymphoma.